NMRA Live signals | Maximize Profits with Getagraph.com

BUY 121136 min ago

@ $18.19

Issued: 14 Feb 2024 @ 12:07

Return: -48.21%

Previous signal: Feb 14 - 11:05

Previous signal: Sell

Return: -1.41 %

Live Chart Being Loaded With Signals

Commentary (8 May 2024 @ 16:00):

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases...

Stats
Today's Volume	412 520
Average Volume	607 950
Market Cap	1.50B
EPS	$0 ( 2024-03-13 )
Next earnings date	( $-0.350 ) 2024-06-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.60
ATR14	$0.0160 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-08	Arch Venture Partners Xii, Llc	Buy	1 176 593	Common Stock
2023-12-08	Arch Venture Partners Xii, Llc	Buy	703 061	Common Stock
2023-12-08	Arch Venture Partners X, Llc	Buy	1 176 593	Common Stock
2023-12-08	Arch Venture Partners X, Llc	Buy	703 061	Common Stock
2023-12-08	Burow Kristina	Buy	1 176 593	Common Stock

INSIDER POWER
35.65
Last 85 transactions
Buy: 48 806 253 \| Sell: 23 661 663

Volume Correlation

Long: 0.15 (neutral)

Short: -0.43 (neutral)

Signal:(70.152) Neutral

Neumora Therapeutics, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Neumora Therapeutics, Correlation - Currency/Commodity

0.15
( neutral )

-0.33
( neutral )

0.00
( neutral )

-0.38
( neutral )

-0.77
( moderate negative )

-0.08
( neutral )

Neumora Therapeutics, Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.860

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.860

Financial Reports:

No articles found.

Neumora Therapeutics,

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.